{"entity":{"id":"nct05909904","kind":"trial","name":"A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma","aka":[],"tldr":"A phase 2 trial of Alcestobart run by BeiGene, completed.","summary":"A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma is a phase 2 interventional study registered as NCT05909904 by BeiGene, with 160 participants enrolled, started 2023-08-02. Conditions recorded: Head and Neck Squamous Cell Carcinoma and Head and Neck Cancer. Interventions recorded: Tislelizumab, BGB-A425 and LBL-007.","status":"completed","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT05909904","url":"https://clinicaltrials.gov/study/NCT05909904"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":["alcestobart"],"companies":["nanjing-leads-biolabs"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05909904","phase":"2","setting":"A Randomized, Phase 2, Open-Label, Multi-Arm Study of Tislelizumab in Combination With Investigational Agents as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","sponsor":"BeiGene","enrolled":160,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05909904/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"}],"drug":[{"id":"alcestobart","kind":"drug","name":"Alcestobart","route":"/drugs/alcestobart/"}],"company":[{"id":"nanjing-leads-biolabs","kind":"company","name":"Nanjing Leads Biolabs","route":"/companies/nanjing-leads-biolabs/"}]}}